Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease

Serge Gauthier; Rémi Bouchard; Albert Lamontagne; Peter Bailey; Howard Bergman; Jack Ratner; Yoseph Tesfaye; Monique Saint-Martin; Yves Bacher; Louise Carrier; Roland Charbonneau; A. Mark Clarfield; Brian Collier; Dolly Dastoor; Louise Gauthier; Marcel Germain; Catherine Kissel; Monique Krieger; Seymour Kushnir; Hélène Masson; Jacques Morin; Vasavan Nair; Leonard Neirinck; Samy Suissa

Journal ArticleOPEN ACCESS

Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease

Gauthier S
Bouchard R
Lamontagne A
et al.

New England Journal of Medicine (1990) 322(18) 1272-1276

DOI: 10.1056/nejm199005033221804

N/ACitations

8Readers

Abstract

Abstract We studied the efficacy and safety of oral tetrahydroaminoacridine (THA) combined with lecithin in 52 patients with Alzheimer's disease. The maximal tolerated dose of THA (up to 100 mg per...

Cite

CITATION STYLE

APA

Gauthier, S., Bouchard, R., Lamontagne, A., Bailey, P., Bergman, H., Ratner, J., … Suissa, S. (1990). Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer’s Disease. New England Journal of Medicine, 322(18), 1272–1276. https://doi.org/10.1056/nejm199005033221804

Tetrahydroaminoacridine–Lecithin Combination Treatment in Patients with Intermediate-Stage Alzheimer's Disease

Abstract

Cite

Register to see more suggestions